1 min read
GT Biopharma Posts $3.5 Million Q3 Loss, Projects Runway Into Q3 2027
It had about $10 million in cash on Sept. 30, 2026, after posting net income of $8.3 million in the year-earlier quarter.

GT Biopharma, Inc. posted a net loss of about $3.5 million for the third quarter of 2026, compared with net income of $8.3 million in the same quarter a year earlier.
The company had about $10 million in cash as of Sept. 30, 2026. It expects that balance to provide a cash runway into the third quarter of 2027.